BACKGROUND: A large proportion of patients do not persist with osteoporosis (OP) therapy. Gastrointestinal (GI) events (e.g., gastroesophageal reflux disease and nausea/vomiting) are common among OP patients receiving OP therapy and may impact persistence with treatment.
O steoporosis is a disease characterized by reduced bone mineral density and deterioration of bone microarchitecture. In the United States, there are an estimated 10 million people who have osteoporosis, and an additional 43 million have low bone density. 1 By 2020, it is expected that half of all Americans over 50 will be diagnosed with osteoporosis or develop clinically significant low bone density. 2 Pharmacotherapy is recommended for patients diagnosed with osteoporosis and those at high risk for fragility fractures. 3 The U.S. Food and Drug Administration had approved several agents for the treatment of osteoporosis, including bisphosphonates (e.g., alendronate, risedronate, ibandronate, and zoledronic acid); calcitonin; selective estrogen receptor modulators (e.g., raloxifene); parathyroid hormone (e.g., teriparatide); and the receptor activator of nuclear factor-kappa B ligand (RANKL) inhibitor (denosumab) during the 2002-2010 time frame. Among osteoporosis treatments, oral bisphosphonates are currently considered the first-line treatment option, with more than 150 million bisphosphonate prescriptions dispensed from [2005] [2006] [2007] [2008] [2009] in the United States alone. 4 However, suboptimal compliance and low persistence to osteoporosis medication pose significant challenges for reducing the risk of fragility fracture. 5, 6 Even though medication compliance is strongly linked to reduction in fracture risk, [7] [8] [9] [10] [11] several studies have indicated that compliance with osteoporosis medication is suboptimal as evidenced by a medication possession ratio less than 0.8. [12] [13] [14] Additionally, many patients started on osteoporosis medication do not persist with treatment. 9, 10, [15] [16] [17] Approximately 50% or more of patients newly started on bisphosphonates discontinue treatment within 12
• Osteoporosis treatment significantly decreases the risk of fragility fracture. However, many patients do not persist with osteoporosis therapy long enough to gain the protective benefits of therapy.
• Gastrointestinal symptoms have been linked with osteoporosis therapy discontinuation in clinical practice.
What is already known about this subject
• This study evaluated the association between post-treatment gastrointestinal events and treatment discontinuation and switching patterns among women during the first year of oral bisphosphonate treatment.
• Following initiation of oral bisphosphonate therapy, women who experienced gastrointestinal events were 36% more likely to discontinue therapy or switch to nonbisphosphonates than women who did not experience gastrointestinal events while on therapy.
sion, diabetes, fatigue, GI mucositis and urination problems, hyperparathyroidism, hypertension, inflammatory bowel disease, inflammatory joint disease, or vitamin D deficiency); Deyo-Charlson Comorbidity Index (CCI); 28 and medication use (estrogen, gastroprotective agents, glucocorticoid, and nonsteroidal anti-inflammatory drugs [NSAIDs] ). Osteoporosisrelated fractures (i.e., fragility fractures) were defined based on ICD-9-CM codes in the primary or secondary position from all medical and inpatient claims. Fractures of the hip (femur neck), vertebra, as well as nonvertebral fractures (pelvis, humerus, forearm, other femoral sites, tibia, fibula, rib, clavicle, scapula, and trunk) were included. The ICD-9-CM codes used to identify osteoporotic fractures are described in the Appendix. Fractures of hand, skull, digits, feet and ankle, and any open fractures were not considered as osteoporosisrelated fractures. 29 Fractures of the same site were defined as distinct fractures if the occurrences were at least 30 days apart.
The occurrence of GI events was assessed during the baseline period and at 3, 6, and 12 months of follow-up (i.e., post-treatment). GI events and their severity classification were defined by the presence of relevant ICD-9-CM codes in the primary and/or secondary position from all medical or inpatient claims. The list of GI events, encompassing minor symptoms such as heartburn and nausea through major acute conditions such as GI hemorrhage and ulcers, is shown in the Appendix. Certain ICD-9-CM codes, typically those involving hemorrhage or perforation, were classified as serious GI events. The proportion of patients with GI events was defined as the percentage of individuals having at least 1 GI event and was calculated at baseline and at 3, 6, and 12 months in the follow-up period.
Treatment patterns assessed during follow-up were persistence, discontinuation, switching, and augmentation. Persistence was defined as continuous refills of the index drug class, without additional drug therapy from a different drug class, from the index date until the end of the follow-up period with no gaps in days supply greater than 45 days. The use of 45 days as the allowable gap was determined based on the fact that a typical prescription of oral bisphosphonate is usually 30 days, and we allowed a "leeway" of up to 1.5 times the typical duration of a prescription refill. Discontinuation was defined as the first gap in supply greater than 45 days at any time from the index date to the end of the follow-up period.
Switching was defined as a change in the index drug class, that is, from a bisphosphonate to a nonbisphosphonate, with discontinuation of the index drug class. For example, a medication change from ibandronate to raloxifene was considered a switch because these drugs represent different classes, while a medication change from alendronate to ibandronate was not considered a switch because both are within the bisphosphonate class.
Augmentation was defined as a new drug prescription for a nonindex drug class being observed while the index drug class months of initiation and, as a consequence, experience significantly higher risk of fracture compared with persistent patients. 15, [18] [19] [20] [21] [22] [23] Multiple studies indicate that medication side effects may be one of the key factors influencing patients' suboptimal treatment persistence and adherence behavior. [24] [25] [26] Gastrointestinal (GI) events are common among patients receiving bisphosphonate therapy for the treatment of osteoporosis. GI events may significantly affect medication tolerability. Woo et al. (2010) recently conducted a prospective analysis that concluded that having any GI events at study entry was associated with increased therapy discontinuation. 27 However, there is limited evidence examining the association between GI events and treatment persistence within a managed care setting in the United States.
The purpose of this study was to estimate the proportion of patients with GI events post-treatment initiation and examine the association between GI events and osteoporosis treatment persistence in a U.S. managed care population.
■■ Methods Design and Data Source
The retrospective cohort study was conducted using the i3 InVision Data Mart (now the Optum Clinformatics Data Mart). This large, national U.S. claims database contains de-identified patient information, including demographic characteristics and medical and pharmacy claims data. Medical claims include International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedures codes. The outpatient pharmacy claims data contain National Drug Code numbers for dispensed medications. Over 3 million patients with a diagnosis of osteoporosis, osteoporosis-related fracture, and/or a prescription for a medication used to treat or prevent osteoporosis were included in the database during the study period from January 2001 through December 2010.
Sample Selection
Women aged 55 years and older were eligible for the study if they initiated oral bisphosphonate (alendronate, ibandronate, or risedronate) therapy from January 1, 2001, through December 31, 2009 (index date is date of first oral bisphosphonate claim) and were continuously enrolled with medical and pharmacy benefits for 1 year before (baseline period) and 1 year after (follow-up period) the index date.
Patients were excluded if they had Paget's disease or a malignant neoplasm during the baseline or follow-up period or had claims for 2 oral osteoporosis therapies on the index date. Analysis of Administrative Claims of a U.S. Managed Care Population was still being refilled. If a patient exhibited multiple treatment patterns (e.g., first switching, then augmenting), the first exhibited pattern was used to define their treatment pattern status for the study. All forms of osteoporosis therapy (oral, injectable, intranasal, and intravenous) were considered in the definition of switching and augmentation, including bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid), calcitonin, denosumab, raloxifene, and teriparatide.
Measures

Statistical Analysis
Baseline characteristics were assessed and compared between patients with and without post-treatment GI events. Differences in baseline characteristics were evaluated using t-tests for continuous variables and chi-square tests for binary and categorical variables.
The association between post-treatment GI events and treatment discontinuation or switching during 12-month follow-up was examined and quantified using Cox regression. In the regression model, the study outcome was time to discontinuation or switch, right censored at end of the 12-month followup. The independent variable of interest was a time-varying variable indicating the occurrence of a post-treatment GI event, censored at discontinuation or switching. Because the patients with baseline GI events could be more prone to posttreatment GI diagnoses than those without baseline GI events, the regression model was developed by stratifying the presence of baseline GI events. Furthermore, the model also included age (grouped as 55-59, 60-69, 70-79, and 80-89), CCI, and the following baseline clinical characteristics expressed as binary variables (presence or absence): comorbid conditions, medication use, and osteoporosis-related fracture, as control variables. In addition, sensitivity analyses were conducted to assess the association for the occurrence of post-treatment GI events within 3 and 6 months before the discontinuation and/or switching. Augmenters were excluded from the regression analysis as only 189 (0.3%) patients in the study were taking 2 osteoporosis medications simultaneously.
■■ Results Patient Selection and Baseline Characteristics
A total of 617,989 women with at least 1 claim for an oral osteoporosis therapy during the index window January 1, 2002-December 31, 2009, were identified, and the final sample included 75,593 eligible patients ( Figure 1 ). The predominant reasons for exclusion were aged less than 55 years as of the index date (n = 239,756, 38.8%) and lack of continuous eligibility with medical and pharmacy benefits during baseline and follow-up (n = 223,412, 36.2%). Mean age at index was 64.4 years ( Table 1) . GI events were diagnosed in 26.6% of the patients in the baseline period, and 3.6% of patients had a serious baseline GI event. There were 4,531 (6.0%) patients with an osteoporotic fracture, and 17.9% of patients used gastroprotective agents. There were several differences in the baseline characteristics among patients who did versus those who did not experience a post-treatment GI event, most notably a higher rate of baseline GI events in patients who subsequently had a post-treatment GI event (48.6% vs. 18.0%). A higher proportion of patients who experienced a post-treatment GI event also had an osteoporotic fracture (7.4% vs. 5.4%), used gastroprotective agents (34.3% vs. 11.5%), and had osteoporosisrelated comorbidities during baseline.
Rate of GI Events
For all patients, the rate of GI events at 3, 6, and 12 months post-treatment was 10.7%, 17.5%, and 28.0%, respectively (Table 2) . Compared with patients who did not experience a baseline GI event (73.4% of patients), patients with a baseline GI event (26.6% of patients) had a higher rate of GI events during the post-treatment period: 23.0% vs. 6.3% during the first 3 months post-treatment, 35.3% vs. 11.1% at 6 months, and 51.2% vs. 19.6% at 12 months. 
Association Between GI Events and Osteoporosis Treatment Persistence
The results of the Cox regression model for the association between post-treatment GI events and the likelihood of discontinuation or switching are shown in Table 4 . Patients with a post-treatment GI event during the 12-month follow-up were 35.6% more likely to discontinue bisphosphonates or switch to nonbisphosphonates than patients without any post-treatment GI event (hazard ratio [HR] = 1.356; 95% confidence interval [CI] = 1.318-1.396). Advanced age (age categories 70-79 and 80-89) increased the risk of discontinuing or switching therapy by 4.2%-6.4%, and higher baseline CCI scores increased the risk by 3.1%. A baseline osteoporosis-related fracture decreased the risk of discontinuation or switching by 5.1%. Baseline use of NSAIDS or glucocorticoids was associated with a 4.8%-7.6% higher risk of discontinuation or switching. The association of a post-treatment GI event with discontinuation or switching was stronger when it occurred within 3 or 6 months before treatment discontinuation or switching. In the sensitivity analysis, a post-treatment GI event within 6 months before treatment discontinuation or switching was associated with 37.9% greater likelihood of discontinuation or switching (HR = 1.379, 95% CI = 1.338-1.421). A post-treatment GI event within 3 months of treatment discontinuation or switching was associated with 45.6% greater risk of discontinuation or switching (HR = 1.456, 95% CI = 1.408-1.505). Estimated effects for other patient characteristics were similar in the 3-month, 6-month, and 12-month analyses.
■■ Discussion
A majority of patients (59.9%) initiating bisphosphonate treatment discontinued therapy in the first year. Most patients who discontinued therapy did so within the first 3 months after treatment initiation. GI events that occurred after treatment initiation were associated with a 36% greater risk of discontinuing bisphosphonate or switching to nonbisphosphonate therapy. The sooner the GI event occurred after initiating treatment, the greater was the risk of discontinuation or switching.
The observed association between GI events and decreased osteoporosis treatment persistence is supported by previous work. In a prospective study of postmenopausal women in the United States, new and continuing users of osteoporosis medication (primarily oral bisphosphonates) who reported any GI side effects at study entry had 39% greater odds of discontinuing therapy by month 6 of the study. 27 A retrospective analysis of patients in California reported that a GI diagnosis in the year prior to initiating alendronate was associated with a 21% lower odds of being persistent in the following year. 19 Similarly, a history of upper GI problems in the year prior to starting bisphosphonate therapy was associated with 7% lower likelihood of being persistent with therapy in United Kingdom patients. 17 Our study adds to the literature on the association between GI events and bisphosphonate discontinuation or switching; we accounted not only for a history of GI events through stratification in the Cox regression model, but we also examined GI events that occurred after bisphosphonate treatment initiation. No causal relationship between use of oral bisphosphonates and occurrence of GI events after initiation of oral bisphosphonates was established in this study. The occurrence of GI events after initiation of oral bisphosphonates 
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analysis that the more recent a GI diagnosis, the stronger its effect on treatment discontinuation or switching. Even though GI events with relatively less severity, such as abdominal pains, may not lead to discontinuation or switching, patients who experienced any GI events after bisphosphonate treatment initiation had significantly greater likelihood of discontinuation or switching. In the main analysis, a post-treatment GI diagnosis increased the likelihood of discontinuation or switching by 35.6%. The association was strengthened when considering only those post-treatment GI diagnoses that occurred within 6 months before discontinuation/switching (HR = 1.379) and the post-treatment GI events that occurred within 3 months (HR = 1.456). This finding further reinforces the clinical implication that the decision to discontinue or switch treatment can be significantly influenced by the presence of GI events after initiation of osteoporosis treatment, especially for patients with a history of GI problems. No causal relationship between occurrence of GI events and discontinuation or switching of may be associated with use of oral bisphosphonates, a common underlying condition, or concomitant treatment, such as NSAIDs or corticosteroids, that would either independently cause or predispose patients to GI problems. The sensitivity analyses for GI events that occurred within 3 and 6 months of treatment discontinuation or switching supported not only the main findings at 12 months but also established a link between the proximity of the post-treatment GI event and likelihood of treatment discontinuation or switching. These results have important clinical implications for osteoporosis treatment in patients with a history of GI events and those who experience GI events post-treatment. Among patients with a GI event within 1 year prior to treatment initiation, 51.2% experienced a GI event during the first 12 months post-treatment, compared with only 19.6% of patients without a pretreatment GI event. Thus, patients with a history of GI events are at an increased risk for experiencing GI events during osteoporosis treatment. We also observed in the sensitivity treatment was established in this study. There are unobserved external factors that can impact this association and were not accounted for in our regression model. The predominant treatment pattern in this study was discontinuation of therapy: 59.9% of patients discontinued bisphosphonate in the first 12 months of treatment, and the mean time to discontinuation occurred soon (115.6 days) after treatment initiation. In previous database studies in the United States and Europe, 17%-58% of patients were persistent with bisphosphonate therapy during the first year of treatment, and our mean persistence rate (39.3%) is within this range. [17] [18] [19] 21, 30 The wide range in previously reported studies is likely a function of differences in study methodology, oral bisphosphonate dosing schedule (e.g., daily vs. weekly), and patient characteristics (e.g., men vs. women). For example, we used a medication supply gap of 45 days or less to define persistence, and the supply gap in earlier studies ranged from 30-183 days, with larger gaps typically resulting in greater persistence rates. [18] [19] [20] Nonpersistence with osteoporosis therapy is associated with greater fracture risk, 10, 17, 20 and efforts to improve persistence are essential to avoid adverse clinical outcomes and their attendant health care costs. Our results suggest a strong link between post-treatment GI events and decreased bisphosphonate treatment persistence in the first year of therapy. The management of osteoporosis patients should include screening of patients with comorbid GI conditions prior to bisphosphonate initiation and proactive follow-up monitoring of GI complaints to improve medication persistence.
Limitations
This study had several limitations, and the results should be considered in this context. The treatment patterns we observed are based on the allowed refill gap of 45 days and may vary depending on the length of the gap considered. The total number of patients with GI events may have been underestimated because only GI events that resulted in a medical service claim were included in this analysis. GI events that did not result in a medical claim may have also influenced the risk for discontinuation and switching, but these events were not accounted for. We only examined the first change in treatment pattern (i.e., augmentation, discontinuation, or switching); it is possible that some patients re-initiated the same or a different osteoporosis therapy during the study interval. The regression model for risk of discontinuation or switching accounted for several patient demographic and clinical characteristics, but there may have been other unidentified or unmeasured factors that influenced the risk of discontinuation or switching. For example, we did not measure the presence of bone mineral density testing at baseline, which has been associated with higher rates of compliance with bisphosphonate therapy.
